Cross-Border Deals: The Right Prescription for Animal Health
|As the humanization of pets continues and pet lifespans grow longer, investment opportunities in animal health abound. While most animal health companies will first look for growth within their own borders, global consolidation and expansion is rising in popularity because companies are struggling to grow revenue close to home and sector trends and attributes are similar across global markets.
Lincoln International experts in the animal health sector share their perspectives on considerations for investors interested in cross-border mergers and acquisitions in the space.
- Click here to download a printable version of this perspective.
- Sign up to receive Lincoln's perspectives
Subsector Consolidation to Watch
In the diverse world of animal health, four subsectors in particular have been active in exploring cross-border consolidation—pharmaceutical manufacturers, diagnostic and lab organizations, veterinary hospitals and distributors.
Five large pharmaceutical players dominate the animal health manufacturing market—Merck, Elanco, Ceva Animal Health, Zoetis and Boehringer Ingelheim. With antitrust regulations preventing these companies from making additional large acquisitions in the pharmaceutical markets, these players are forced to look outside their core businesses and core geographies to make acquisitions that will move the needle and continue to push growth.
Diagnostic and lab organizations are in similar positions. Mars, Heska Corporation, Zoetis and Idexx Laboratories dominate the diagnostic and lab sector and need to expand their geographic reach and diversify their capabilities to continue their organic growth. For example, in 2020 U.S.-based Zoetis acquired UK-based Virtual Recall to offer improved service and communication offerings to veterinary practices. The driver was partly diversification but also to expand relationships with the vet and be seen as a service ‘partner,’ rather than someone pushing a product or a drug—driving growth in their core business through the relationship. Additionally, Heska entered Europe in 2020 with the acquisition of Scil from Covetrus.
For veterinary hospitals, consolidation has occurred at a rapid clip and at some point players will need to look across borders to continue to grow. This is especially true in the UK where significant consolidation has already occurred, leading to searches for targets in Europe with providers like Vet Partners, IVC, Mars and recently Medivet, all spending time and money to grow their European footprint.
Distributors are feeling the margin pressure from the large pharmaceutical manufacturers supplying the product and from the continued consolidation of the veterinary hospitals buying the product. Distributors will have to diversify their current business models if they are to remain competitive.
As corporates look to achieve economies of scale, they need to evaluate geographic restrictions and diversify—in both their geographic location and offerings. For private equity investors, who are likely to create platforms in a singular animal health subsector, geographic diversification is key.
Lincoln International identified the following items to consider for investors interested in cross-border M&A:
To find success, those interested in pursuing consolidation in the animal health space need to work with advisors that have global reach and not only understand the pet space but also healthcare holistically. Connect with Lincoln International bankers to learn how their global network and industry knowledge can help you today.
Meet Professionals with Complementary Expertise
What Price is Right? Trends and Opportunities for Private Equity in Pharma Market Access
The cost of developing new drugs is staggering. Among the top 20 global biopharmas, the average cost of developing a candidate from discovery through clinical trials to market was approximately… Read More
Investment Opportunities in Pharma: A Data-Driven Exploration of CDMO Appeal
The report discusses the current state of the contract development and manufacturing organization (CDMO) market within the pharmaceutical industry, emphasizing the increased interest from private equity (PE) investors. The pharmaceutical… Read More
Scrip Asks…What Does 2024 Hold for Biopharma?
James West, Managing Director in Lincoln’s Healthcare Group, recently discussed his expectations for the biopharma market in 2024 as part of Scrip’s series. Part One – Business Strategy and Leadership… Read More
Recent Transactions in Healthcare
Lincoln International advised Aquiline Capital Partners on the acquisition of Health Prime from GPB Capital Holdings
Lincoln International advised Talisman Capital Partners on the sale of ADVOCATE RCM to Ventra Health, a portfolio company of Varsity Healthcare Partners
Lincoln International advised Mars on the sale of Diamond Animal Health to Veterinary Pharmaceutical Solutions, a portfolio company of Granite Creek Capital Partners
Lincoln International advised 7Mind on its sale to Gymondo, a portfolio company of Oakley Capital
Lincoln International advised Olive AI on the sale of substantially all of its assets to Waystar and Humata Health
Lincoln International advised EQT on the acquisition of a controlling stake in Indira IVF from TA Associates and promoter family
Lincoln International advised Scantox Group, a portfolio company of Impilo, on its acquisition of QPS Austria’s Neuropharmacology Division
Lincoln International advised Seven Hills Capital on raising capital for Reliable Medical